HBeAg-Positive Chronic Hepatitis B
Study 437 was a randomized, double-blind, placebo-controlled, three-arm-study in patients with HBeAg-positive chronic hepatitis B that allowed for a comparison between placebo and Adefovir Dipivoxil Tablets. The median age of patients was 33 years. Seventy-four percent were male, 59% were Asian, 36% were Caucasian, and 24% had prior interferon-α treatment. At baseline, patients had a median total Knodell Histology Activity Index (HAI) score of 10, a median serum HBV DNA level as measured by the Roche Amplicor Monitor polymerase chain reaction (PCR) assay (LLOQ = 1000 copies/mL) of 8.36 log
10 copies/mL and a median ALT level of 2.3 times the upper limit of normal.
HBeAg-Negative (Anti-HBe Positive/HBV DNA Positive) Chronic Hepatitis B
Study 438 was a randomized, double-blind, placebo-controlled study in patients who were HBeAg-negative at screening, and anti-HBe positive. The median age of patients was 46 years. Eighty-three percent were male, 66% were Caucasian, 30% were Asian and 41% had prior interferon-α treatment. At baseline, the median total Knodell HAI score was 10, the median serum HBV DNA level as measured by the Roche Amplicor Monitor PCR assay (LLOQ = 1000 copies/mL) was 7.08 log
10 copies/mL, and the median ALT was 2.3 times the upper limit of normal.
The primary efficacy endpoint in both studies was histological improvement at Week 48; results of which are shown in Table 4.
Table 4 Histological Response at Week 48
a | Study 437 | Study 438 |
Adefovir Dipivoxil Tablets
10 mg
(N=168)
| Placebo
(N=161)
| Adefovir Dipivoxil Tablets 10 mg
(N=121)
| Placebo
(N=57)
|
| Improvement
b | 53% | 25% | 64% | 35% |
| No Improvement | 37% | 67% | 29% | 63% |
| Missing/Unassessable Data | 10% | 7% | 7% | 2% |
a Intent-to-Treat population (patients with ≥1 dose of study drug) with assessable baseline biopsies.
b Histological improvement defined as ≥2 point decrease in the Knodell necro-inflammatory score with no worsening of the Knodell fibrosis score.
Table 5 illustrates the changes in Ishak Fibrosis Score by treatment group.
Table 5 Changes in Ishak Fibrosis Score at Week 48
Number of Adequate
Biopsy Pairs
| Study 437 | Study 438 |
Adefovir Dipivoxil Tablets 10 mg
(N=152)
| Placebo
(N=149)
| Adefovir Dipivoxil Tablets 10 mg
(N=113)
| Placebo
(N=56)
|
Ishak Fibrosis Score
Improved
a | 34% | 19% | 34% | 14% |
| Unchanged | 55% | 60% | 62% | 50% |
| Worsened
a | 11% | 21% | 4% | 36% |
a Change of 1 point or more in Ishak Fibrosis Score.
At Week 48, improvement was seen with respect to mean change in serum HBV DNA (log
10 copies/mL), normalization of ALT, and HBeAg seroconversion as compared to placebo in patients receiving Adefovir Dipivoxil Tablets (Table 6).
Table 6 Change in Serum HBV DNA, ALT Normalization, and HBeAg Seroconversion at Week 48
| Study 437 | Study 438 |
Adefovir Dipivoxil Tablets 10 mg
(N=171)
| Placebo
(N=167)
| Adefovir Dipivoxil Tablets 10 mg
(N=123)
| Placebo
(N=61)
|
| Mean change ± SD in serum HBV DNA form baseline (log
10 copies/mL)
| -3.57 ± 1.64 | -0.98 ± 1.32 | -3.65 ± 1.14 | -1.32 ± 1.25 |
| ALT normalization | 48% | 16% | 72% | 29% |
| HBeAg seroconversion | 12% | 6% | NA
a | NA
a |
a Patients with HBeAg-negative disease cannot undergo HBeAg seroconversion.
Treatment Beyond 48 Weeks
In Study 437, continued treatment with Adefovir Dipivoxil Tablets to 72 weeks resulted in continued maintenance of mean reductions in serum HBV DNA observed at Week 48. An increase in the proportion of patients with ALT normalization was also observed in Study 437. The effect of continued treatment with Adefovir Dipivoxil Tablets on seroconversion is unknown.
In Study 438, patients who received Adefovir Dipivoxil Tablets during the first 48 weeks were re-randomized in a blinded manner to continue on Adefovir Dipivoxil Tablets or receive placebo for an additional 48 weeks. At Week 96, 50 of 70 (71%) of patients who continued treatment with Adefovir Dipivoxil Tablets had undetectable HBV DNA levels (less than 1000 copies/mL), and 47 of 64 (73%) of patients had ALT normalization. HBV DNA and ALT levels returned towards baseline in most patients who stopped treatment with Adefovir Dipivoxil Tablets.
From 141 eligible patients, there were 125 (89%) patients in Study 438 who chose to continue Adefovir Dipivoxil Tablets for up to 192 weeks or 240 weeks (4 years or 5 years). As these patients had already received Adefovir Dipivoxil Tablets for at least 48 weeks and appeared to be experiencing a benefit, they are not necessarily representative of patients initiating Adefovir Dipivoxil Tablets. Of these patients, 89/125 (71%) and 47/70 (67%) had an undetectable HBV DNA level (less than 1000 copies/mL) at Week 192 and Week 240, respectively. Of the patients who had an elevated ALT at baseline, 77/104 (74%) and 42/64 (66%) had a normal ALT at Week 192 and Week 240, respectively. Six (5%) patients experienced HBsAg loss.